Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

Published: June 2016
No. of Pages: 70

GBI Research’s latest report, ""Innovation Tracking Factbook 2016An Assessment of the Pharmaceutical Pipeline"" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.


  • What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
  • The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
  • What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
  • What factors have been driving the increasing number of first-in-class product approvals over recent decades?
  • What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
  • What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

Reasons to buy

This report will allow you to -

  • Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
  • Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one’s own strategic positioning against this backdrop
  • Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
  • Make key decisions about the role of innovation within one’s own pipeline portfolio

Published By: CBR Pharma Insights
Product Code: CBR Pharma Insights67

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: